首页 > 最新文献

Seminars in reproductive medicine最新文献

英文 中文
Weight Cycling in Women: Adaptation or Risk? 女性体重循环:适应还是风险?
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0040-1721418
Katelyn J Carey, Wendy Vitek

Obesity, dieting, and weight cycling are common among reproductive-age women. Weight cycling refers to intentional weight loss followed by unintentional weight regain. Weight loss is accompanied by changes in gut peptides, adipose hormones, and energy expenditure that promote weight regain to a tightly regulated set point. While weight loss can improve body composition and surrogate markers of cardiometabolic health, it is hypothesized that the weight regain can result in an overshoot effect, resulting in excess weight gain, altered body composition, and negative effects on surrogate markers of cardiometabolic health. Numerous observational studies have examined the association of weight cycling and health outcomes. There appears to be modest association between weight cycling with type 2 diabetes mellitus and dyslipidemia in women, but no association with hypertension, cardiovascular events, and overall cancer risk. Interestingly, mild weight cycling may be associated with a decreased risk of overall and cardiovascular mortality. Little is known about the effects of weight cycling in the preconception period. Although obesity and weight gain are associated with pregnancy complications, preconception weight loss does not appear to mitigate the risk of most pregnancy complications related to obesity. Research on preconception weight cycling may provide insight into this paradox.

肥胖、节食和体重循环在育龄妇女中很常见。体重循环指的是有意减重之后又无意反弹的情况。体重减轻伴随着肠道肽、脂肪激素和能量消耗的变化,这些变化促进体重恢复到一个严格调节的设定值。虽然减肥可以改善身体组成和心脏代谢健康的替代指标,但据推测,体重反弹可能会导致超调效应,导致体重过度增加,改变身体组成,并对心脏代谢健康的替代指标产生负面影响。许多观察性研究已经检验了体重循环和健康结果之间的关系。体重循环与女性2型糖尿病和血脂异常之间似乎有一定的关联,但与高血压、心血管事件和总体癌症风险没有关联。有趣的是,轻度的体重循环可能与总体死亡率和心血管死亡率的降低有关。人们对孕前期体重循环的影响知之甚少。虽然肥胖和体重增加与妊娠并发症有关,但孕前体重减轻似乎并不能减轻大多数与肥胖有关的妊娠并发症的风险。对孕前体重循环的研究可能会让我们对这个悖论有所了解。
{"title":"Weight Cycling in Women: Adaptation or Risk?","authors":"Katelyn J Carey,&nbsp;Wendy Vitek","doi":"10.1055/s-0040-1721418","DOIUrl":"https://doi.org/10.1055/s-0040-1721418","url":null,"abstract":"<p><p>Obesity, dieting, and weight cycling are common among reproductive-age women. Weight cycling refers to intentional weight loss followed by unintentional weight regain. Weight loss is accompanied by changes in gut peptides, adipose hormones, and energy expenditure that promote weight regain to a tightly regulated set point. While weight loss can improve body composition and surrogate markers of cardiometabolic health, it is hypothesized that the weight regain can result in an overshoot effect, resulting in excess weight gain, altered body composition, and negative effects on surrogate markers of cardiometabolic health. Numerous observational studies have examined the association of weight cycling and health outcomes. There appears to be modest association between weight cycling with type 2 diabetes mellitus and dyslipidemia in women, but no association with hypertension, cardiovascular events, and overall cancer risk. Interestingly, mild weight cycling may be associated with a decreased risk of overall and cardiovascular mortality. Little is known about the effects of weight cycling in the preconception period. Although obesity and weight gain are associated with pregnancy complications, preconception weight loss does not appear to mitigate the risk of most pregnancy complications related to obesity. Research on preconception weight cycling may provide insight into this paradox.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"277-282"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1055/s-0040-1721418","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9247650","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review. 确认宫内妊娠前药物流产:系统综述。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1760117
Karin Brandell, John J Reynolds-Wright, Clare Boerma, Gillian Gibson, Helena Hognert, Heera Tuladhar, Oskari Heikinheimo, Sharon Cameron, Kristina Gemzell-Danielsson

"Very early medical abortion" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (n = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.

“极早期药物流产”(VEMA)是指超声显示宫内妊娠前药物流产(米非司酮和米索前列醇联合用药)。我们的目的是介绍目前关于VEMA的有效性、安全性(重点是异位妊娠)以及如何评估VEMA治疗成功的证据。我们对报道VEMA结果的研究进行了系统回顾。该领域很小,因此我们的目标是绘制所有相关文献,而不进行荟萃分析。我们在2022年4月19日检索了PubMed, Medline和Embase。我们对证据进行了叙述综合。共鉴定出373件物品。6篇文章(代表4篇观察性试验和1篇试点试验)被纳入最终综述。在所有纳入的研究中,治疗效果在91%到100%之间。异位妊娠的发生率较低,报告的破裂病例极少(n = 2)。大多数研究使用连续血清人绒毛膜促性腺激素(s-hCG)水平来确定流产成功率;一项研究使用低敏感性尿hCG。从现有的证据来看,VEMA似乎是有效的,似乎不会对异位妊娠造成伤害。可以通过流产前和流产后的s-hCG来评估治疗。需要高质量的随机对照试验证据来为实践提供最佳信息。
{"title":"Medical Abortion before Confirmed Intrauterine Pregnancy: A Systematic Review.","authors":"Karin Brandell,&nbsp;John J Reynolds-Wright,&nbsp;Clare Boerma,&nbsp;Gillian Gibson,&nbsp;Helena Hognert,&nbsp;Heera Tuladhar,&nbsp;Oskari Heikinheimo,&nbsp;Sharon Cameron,&nbsp;Kristina Gemzell-Danielsson","doi":"10.1055/s-0042-1760117","DOIUrl":"https://doi.org/10.1055/s-0042-1760117","url":null,"abstract":"<p><p>\"Very early medical abortion\" (VEMA) refers to medical abortion (with mifepristone and misoprostol) before intrauterine pregnancy is visualized on ultrasound. Our aim is to present the current evidence on efficacy, safety (focused on ectopic pregnancies), and how to assess treatment success of VEMA. We conducted a systematic review of studies reporting outcomes of VEMA. The field is small and so our objective was to map all relevant literature, without conducting meta-analysis. We searched PubMed, Medline, and Embase on April 19, 2022. We conducted a narrative synthesis of the evidence. A total of 373 articles were identified. Six articles (representing four observational and one pilot trial) were included in the final review. Across all included studies, treatment efficacy ranged between 91 and 100%. Prevalence of ectopic pregnancy was low and very few cases (<i>n</i> = 2) of ruptures were reported. Most studies used serial serum human chorionic gonadotrophin (s-hCG) levels to determine success of abortion; one study used low sensitivity urine hCG. From the available evidence, VEMA appears to be efficacious and does not appear to cause harm to ectopic pregnancies. Treatment can be assessed with pre- and postabortion s-hCG. Good quality, randomized controlled trial evidence is needed to best inform practice.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"258-263"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10673657","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Measures of Pregnancy Intention: Why Use Them and What Do They Tell Us? 怀孕意向的测量:为什么要使用它们,它们告诉我们什么?
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1760118
Edwina Dorney, Geraldine Barrett, Jennifer Hall, Kirsten I Black

Understanding pregnancy intention is an important public health measure that captures the ability of individuals to access information, resources, and services needed to plan the timing and spacing of pregnancies. Pregnancy intention is a complex construct impacted by social, emotional, financial, cultural, and contextual factors. In this review, we will examine the range of available tools for individuals and populations to evaluate pregnancy intention, the timing of the tools in relation to pregnancy, their interpretation, and use for policy and practice. Traditionally, pregnancy intention was only assessed in population health surveys; however, more sophisticated tools and measures have been developed. These tools can be used at several time points: before pregnancy, during pregnancy, or after the pregnancy has ended. It is important to appreciate the varied contexts globally for women and their partners when assessing pregnancy intention, and the ability of a given tool to capture this when used retrospectively or prospectively. These tools can inform targeted delivery of services for a person or couple before, during, and after pregnancy. This knowledge can inform strategies at an individual, community, and population level as an indicator of access to sexual and reproductive health information and knowledge and uptake of preconception health.

了解怀孕意图是一项重要的公共卫生措施,它能够了解个人获得计划怀孕时间和间隔所需的信息、资源和服务的能力。怀孕意向是一个复杂的结构,受社会、情感、经济、文化和背景因素的影响。在这篇综述中,我们将研究个人和人群评估怀孕意图的可用工具的范围、与怀孕有关的工具的时间、它们的解释以及在政策和实践中的使用。传统上,怀孕意向只在人口健康调查中进行评估;然而,更复杂的工具和措施已经开发出来。这些工具可以在几个时间点使用:怀孕前、怀孕期间或怀孕结束后。在评估怀孕意图时,重要的是要了解全球妇女及其伴侣的不同背景,以及在回顾性或前瞻性使用特定工具时捕捉这一点的能力。这些工具可以为个人或夫妇在怀孕前、怀孕期间和怀孕后提供有针对性的服务提供信息。这方面的知识可以为个人、社区和人口各级的战略提供信息,作为获得性健康和生殖健康信息和知识以及接受孕前健康的指标。
{"title":"Measures of Pregnancy Intention: Why Use Them and What Do They Tell Us?","authors":"Edwina Dorney,&nbsp;Geraldine Barrett,&nbsp;Jennifer Hall,&nbsp;Kirsten I Black","doi":"10.1055/s-0042-1760118","DOIUrl":"https://doi.org/10.1055/s-0042-1760118","url":null,"abstract":"<p><p>Understanding pregnancy intention is an important public health measure that captures the ability of individuals to access information, resources, and services needed to plan the timing and spacing of pregnancies. Pregnancy intention is a complex construct impacted by social, emotional, financial, cultural, and contextual factors. In this review, we will examine the range of available tools for individuals and populations to evaluate pregnancy intention, the timing of the tools in relation to pregnancy, their interpretation, and use for policy and practice. Traditionally, pregnancy intention was only assessed in population health surveys; however, more sophisticated tools and measures have been developed. These tools can be used at several time points: before pregnancy, during pregnancy, or after the pregnancy has ended. It is important to appreciate the varied contexts globally for women and their partners when assessing pregnancy intention, and the ability of a given tool to capture this when used retrospectively or prospectively. These tools can inform targeted delivery of services for a person or couple before, during, and after pregnancy. This knowledge can inform strategies at an individual, community, and population level as an indicator of access to sexual and reproductive health information and knowledge and uptake of preconception health.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"229-234"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683177","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Improving Access to and Quality of Postpartum Contraception Provision. 提高产后避孕的可及性和质量。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1758114
Michelle Cooper, Sharon Cameron

Sexual activity and fertility can resume shortly after childbirth, but there are barriers to contraceptive access in the postpartum period. Unintended pregnancy and short interpregnancy intervals (of less than one year) can increase the risk of obstetric and neonatal complications. The antenatal period presents an opportunity to discuss contraceptive options, many of which can be safely initiated immediately after childbirth. Successful delivery of a postpartum contraception program requires an adequate number of maternity staff trained to provide the full range of methods.

性活动和生育能力可以在分娩后不久恢复,但在产后期间获得避孕药具存在障碍。意外怀孕和妊娠间隔短(少于一年)可增加产科和新生儿并发症的风险。产前期提供了一个讨论避孕选择的机会,其中许多可以在分娩后立即安全开始。产后避孕方案的成功实施需要足够数量的经过培训的产科工作人员提供全面的避孕方法。
{"title":"Improving Access to and Quality of Postpartum Contraception Provision.","authors":"Michelle Cooper,&nbsp;Sharon Cameron","doi":"10.1055/s-0042-1758114","DOIUrl":"https://doi.org/10.1055/s-0042-1758114","url":null,"abstract":"<p><p>Sexual activity and fertility can resume shortly after childbirth, but there are barriers to contraceptive access in the postpartum period. Unintended pregnancy and short interpregnancy intervals (of less than one year) can increase the risk of obstetric and neonatal complications. The antenatal period presents an opportunity to discuss contraceptive options, many of which can be safely initiated immediately after childbirth. Successful delivery of a postpartum contraception program requires an adequate number of maternity staff trained to provide the full range of methods.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"235-239"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10673658","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Sexual and Reproductive Health. 性健康和生殖健康。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1759553
Danielle Mazza, Jessica R Botfield
Contraception, preconception care, and abortion are integral and intertwined aspects of women’s reproductive health.We know that nearly half of all pregnancies worldwide are unintended, which can have significant consequences for women, girls, and society more broadly.1 Over 60% of unintended pregnancies, and almost 30% of all pregnancies, end in abortion (noting that nearly half of all abortions performed globally are unsafe).1 Most unintended pregnancies can be attributed to nonor incorrect use of contraception or contraceptive failure,2,3 yet there are approximately 257 million women globally who want to avoid pregnancy but are not using a safe,modernmethod of contraception due to lack of access.1 It is therefore imperative that women are able to access effective methods of contraception, support in pregnancy planning, and abortion care so they can achieve their reproductive life goals. In this issue, we address these aspects of reproductive health. We examine the tools available to evaluate pregnancy intention and the implications of their use for policy and practice. Understanding pregnancy intentions can help women (and the clinicians supporting them)make decisions about contraception to suit their needs. We explore the opportunities for increasing access to effective contraception, using examples from the Australian context, and consider how to improve access to and quality of postpartum contraception provision. We present a common clinical scenario, that of obesity amongwomen of reproductive age seeking contraception and discuss the considerations and approaches for facilitating provision of inclusive contraceptive care for this population group. This includes a review of current evidence on method-specific advantages and disadvantages for people with obesity to guide practice and policy. Finally, we present several articles relating to medical abortion, including a systematic review relating to another common clinical scenario, that of very early medical abortion (VEMA), to report thecurrentevidenceonefficacy, safety, and treatment success of VEMA. We conclude with two case studies from Canada: one focused on access to abortion care for incarcerated people and another on the deregulation ofmedical abortion to support access to safe, early abortion care in primary care settings. The articles in this issue will be of interest to clinicians as well as public health–focused researchers and decision-makers. The issue provides an overviewof current global challenges in reproductive health and provides reviews of the evidence to guide clinical practice and public health responses to key issues relating to pregnancy intention, contraception, and abortion care.
{"title":"Sexual and Reproductive Health.","authors":"Danielle Mazza,&nbsp;Jessica R Botfield","doi":"10.1055/s-0042-1759553","DOIUrl":"https://doi.org/10.1055/s-0042-1759553","url":null,"abstract":"Contraception, preconception care, and abortion are integral and intertwined aspects of women’s reproductive health.We know that nearly half of all pregnancies worldwide are unintended, which can have significant consequences for women, girls, and society more broadly.1 Over 60% of unintended pregnancies, and almost 30% of all pregnancies, end in abortion (noting that nearly half of all abortions performed globally are unsafe).1 Most unintended pregnancies can be attributed to nonor incorrect use of contraception or contraceptive failure,2,3 yet there are approximately 257 million women globally who want to avoid pregnancy but are not using a safe,modernmethod of contraception due to lack of access.1 It is therefore imperative that women are able to access effective methods of contraception, support in pregnancy planning, and abortion care so they can achieve their reproductive life goals. In this issue, we address these aspects of reproductive health. We examine the tools available to evaluate pregnancy intention and the implications of their use for policy and practice. Understanding pregnancy intentions can help women (and the clinicians supporting them)make decisions about contraception to suit their needs. We explore the opportunities for increasing access to effective contraception, using examples from the Australian context, and consider how to improve access to and quality of postpartum contraception provision. We present a common clinical scenario, that of obesity amongwomen of reproductive age seeking contraception and discuss the considerations and approaches for facilitating provision of inclusive contraceptive care for this population group. This includes a review of current evidence on method-specific advantages and disadvantages for people with obesity to guide practice and policy. Finally, we present several articles relating to medical abortion, including a systematic review relating to another common clinical scenario, that of very early medical abortion (VEMA), to report thecurrentevidenceonefficacy, safety, and treatment success of VEMA. We conclude with two case studies from Canada: one focused on access to abortion care for incarcerated people and another on the deregulation ofmedical abortion to support access to safe, early abortion care in primary care settings. The articles in this issue will be of interest to clinicians as well as public health–focused researchers and decision-makers. The issue provides an overviewof current global challenges in reproductive health and provides reviews of the evidence to guide clinical practice and public health responses to key issues relating to pregnancy intention, contraception, and abortion care.","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"227-228"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683174","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Advancing Reproductive Health through Policy-Engaged Research in Abortion Care. 通过堕胎护理政策参与研究促进生殖健康。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-11-01 DOI: 10.1055/s-0042-1760213
Sarah B Munro, Sheila Dunn, Edith R Guilbert, Wendy V Norman

Mifepristone medication abortion was first approved in China and France more than 30 years ago and is now used in more than 60 countries worldwide. It is a highly safe and effective method that has the potential to increase population access to abortion in early pregnancy, closer to home. In both Canada and the United States, the initial regulations for distribution, prescribing, and dispensing of mifepristone were highly restricted. However, in Canada, where mifepristone was made available in 2017, most restrictions on the medication were removed in the first year of its availability. The Canadian regulation of mifepristone as a normal prescription makes access possible in community primary care through a physician or nurse practitioner prescription, which any pharmacist can dispense. In this approach, people decide when and where to take their medication. We explore how policy-maker-engaged research advanced reproductive health policy and facilitated this rapid change in Canada. We discuss the implications of these policy advances for self-management of abortion and demonstrate how in Canada patients "self-manage" components of the abortion process within a supportive health care system.

30多年前,米非司酮药物流产首先在中国和法国获得批准,目前在全球60多个国家使用。这是一种高度安全和有效的方法,有可能增加人们在离家更近的地方获得早期妊娠流产的机会。在加拿大和美国,米非司酮的分销、处方和配药的最初规定都受到高度限制。然而,在加拿大,米非司酮于2017年上市,对该药的大多数限制在其上市的第一年就被取消了。加拿大规定米非司酮作为常规处方,使社区初级保健可以通过医生或执业护士处方获得,任何药剂师都可以配发。在这种方法中,人们决定何时何地服用药物。我们探讨决策者参与的研究如何推进生殖健康政策,并促进加拿大这一快速变化。我们讨论了这些政策进步对堕胎自我管理的影响,并展示了加拿大患者如何在支持性医疗保健系统中“自我管理”堕胎过程的组成部分。
{"title":"Advancing Reproductive Health through Policy-Engaged Research in Abortion Care.","authors":"Sarah B Munro,&nbsp;Sheila Dunn,&nbsp;Edith R Guilbert,&nbsp;Wendy V Norman","doi":"10.1055/s-0042-1760213","DOIUrl":"https://doi.org/10.1055/s-0042-1760213","url":null,"abstract":"<p><p>Mifepristone medication abortion was first approved in China and France more than 30 years ago and is now used in more than 60 countries worldwide. It is a highly safe and effective method that has the potential to increase population access to abortion in early pregnancy, closer to home. In both Canada and the United States, the initial regulations for distribution, prescribing, and dispensing of mifepristone were highly restricted. However, in Canada, where mifepristone was made available in 2017, most restrictions on the medication were removed in the first year of its availability. The Canadian regulation of mifepristone as a normal prescription makes access possible in community primary care through a physician or nurse practitioner prescription, which any pharmacist can dispense. In this approach, people decide when and where to take their medication. We explore how policy-maker-engaged research advanced reproductive health policy and facilitated this rapid change in Canada. We discuss the implications of these policy advances for self-management of abortion and demonstrate how in Canada patients \"self-manage\" components of the abortion process within a supportive health care system.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 5-06","pages":"268-276"},"PeriodicalIF":2.7,"publicationDate":"2022-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10683176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing Adolescent Relationship Abuse in the Context of Reproductive Health Care. 在生殖保健范围内处理青少年关系虐待问题。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2022-03-01 DOI: 10.1055/s-0041-1741519
Maya I Ragavan, Romina L Barral, Kimberly A Randell

Adolescent relationship abuse (ARA) is a significant public health issue that includes physical, sexual, psychological and cyber abuse, reproductive coercion, and/or sexual exploitation within an intimate relationship in which one or both partners is a minor. ARA is associated with numerous negative outcomes that include all domains of health. Many negative outcomes of ARA are related to reproductive and sexual health (RSH); thus, reproductive health care providers must be equipped to recognize and address ARA. This article will review the epidemiology and outcomes of ARA, followed by a discussion of means to robustly address ARA in health care settings. We recommend a strengths-based approach that promotes healthy adolescent relationships, connects adolescents experiencing ARA to harm reduction resources, and equips adolescents to serve as a resource for their peers.

青少年关系虐待是一个重大的公共卫生问题,包括身体、性、心理和网络虐待、生殖强迫和/或在伴侣一方或双方为未成年人的亲密关系中的性剥削。ARA与包括所有卫生领域的许多负面结果有关。ARA的许多负面结果与生殖健康和性健康(RSH)有关;因此,生殖保健提供者必须具备认识和处理ARA的能力。本文将回顾ARA的流行病学和结果,然后讨论在卫生保健机构中强有力地解决ARA的方法。我们建议采取一种基于优势的方法,促进健康的青少年关系,将经历ARA的青少年与减少伤害的资源联系起来,并使青少年成为同龄人的资源。
{"title":"Addressing Adolescent Relationship Abuse in the Context of Reproductive Health Care.","authors":"Maya I Ragavan,&nbsp;Romina L Barral,&nbsp;Kimberly A Randell","doi":"10.1055/s-0041-1741519","DOIUrl":"https://doi.org/10.1055/s-0041-1741519","url":null,"abstract":"<p><p>Adolescent relationship abuse (ARA) is a significant public health issue that includes physical, sexual, psychological and cyber abuse, reproductive coercion, and/or sexual exploitation within an intimate relationship in which one or both partners is a minor. ARA is associated with numerous negative outcomes that include all domains of health. Many negative outcomes of ARA are related to reproductive and sexual health (RSH); thus, reproductive health care providers must be equipped to recognize and address ARA. This article will review the epidemiology and outcomes of ARA, followed by a discussion of means to robustly address ARA in health care settings. We recommend a strengths-based approach that promotes healthy adolescent relationships, connects adolescents experiencing ARA to harm reduction resources, and equips adolescents to serve as a resource for their peers.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"40 1-02","pages":"146-154"},"PeriodicalIF":2.7,"publicationDate":"2022-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9885502/pdf/nihms-1865102.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9374321","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
Prior Thromboembolic Disease and Assisted Reproductive Therapy. 既往血栓栓塞性疾病和辅助生殖治疗。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2021-11-01 Epub Date: 2021-07-14 DOI: 10.1055/s-0041-1732375
Anne Flem Jacobsen, Per Morten Sandset

Assisted reproductive therapy (ART) increases the risk of venous thrombosis (VT) by 2- to 4-fold, whereas pregnancy increases the risk by 5- to 10-fold. Women with a history of VT undergoing ART are often suggested thromboprophylaxis. The literature is scarce and international guidelines are lacking. We made a review of the literature and base our suggestions primarily on expert opinions. We suggest women with a prior VT to use low-molecular-weight heparin as thromboprophylaxis starting from ovarian stimulation, throughout pregnancy, and 6 weeks postpartum. Assessment of VT risk should be done prior to ART. Adjustment of treatment to minimize the thrombotic risk, such as preventing ovarian hyperstimulation syndrome, single-embryo transfer, cryopreservation, and transfer of frozen embryos instead of fresh embryo in high-risk women, is suggested. Women with previous arterial thrombosis should continue aspirin during ART treatment, pregnancy, and postpartum.

辅助生殖治疗(ART)使静脉血栓形成(VT)的风险增加2- 4倍,而怀孕使风险增加5- 10倍。有静脉血栓病史的妇女接受抗逆转录病毒治疗时通常建议进行血栓预防。相关文献很少,也缺乏国际指导方针。我们对文献进行了回顾,并主要以专家意见为基础提出建议。我们建议既往有室性心动过速的妇女使用低分子肝素作为预防血栓的药物,从卵巢刺激开始,贯穿妊娠和产后6周。在抗逆转录病毒治疗前应评估VT风险。建议调整治疗方法以降低血栓形成风险,如预防卵巢过度刺激综合征、单胚胎移植、冷冻保存、高危女性移植冷冻胚胎而非新鲜胚胎。既往有动脉血栓形成的妇女在抗逆转录病毒治疗、妊娠和产后期间应继续服用阿司匹林。
{"title":"Prior Thromboembolic Disease and Assisted Reproductive Therapy.","authors":"Anne Flem Jacobsen,&nbsp;Per Morten Sandset","doi":"10.1055/s-0041-1732375","DOIUrl":"https://doi.org/10.1055/s-0041-1732375","url":null,"abstract":"<p><p>Assisted reproductive therapy (ART) increases the risk of venous thrombosis (VT) by 2- to 4-fold, whereas pregnancy increases the risk by 5- to 10-fold. Women with a history of VT undergoing ART are often suggested thromboprophylaxis. The literature is scarce and international guidelines are lacking. We made a review of the literature and base our suggestions primarily on expert opinions. We suggest women with a prior VT to use low-molecular-weight heparin as thromboprophylaxis starting from ovarian stimulation, throughout pregnancy, and 6 weeks postpartum. Assessment of VT risk should be done prior to ART. Adjustment of treatment to minimize the thrombotic risk, such as preventing ovarian hyperstimulation syndrome, single-embryo transfer, cryopreservation, and transfer of frozen embryos instead of fresh embryo in high-risk women, is suggested. Women with previous arterial thrombosis should continue aspirin during ART treatment, pregnancy, and postpartum.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"180-185"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39183508","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Time-Lapse Systems: A Comprehensive Analysis on Effectiveness. 延时系统:有效性的综合分析。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2021-11-01 Epub Date: 2022-01-10 DOI: 10.1055/s-0041-1742149
Patricia Fadon, Eleanor Gallegos, Salonika Jalota, Lourdes Muriel, Cesar Diaz-Garcia

Time-lapse systems have quickly become a common feature of in vitro fertilization laboratories all over the world. Since being introduced over a decade ago, the alleged benefits of time-lapse technology have continued to grow, from undisturbed culture conditions and round the clock, noninvasive observations to more recent computer-assisted selection of embryos through the development of algorithms. Despite the global uptake of time-lapse technology, its real impact on clinical outcomes is still controversial. This review aims to explore the different features offered by time-lapse technology, discussing incubation, algorithms, artificial intelligence and the regulation of nonessential treatment interventions, while assessing evidence on whether any benefit is offered over conventional technology.

延时系统已迅速成为世界各地体外受精实验室的共同特点。自从十多年前引入延时技术以来,所谓的延时技术的好处不断增加,从不受干扰的培养条件和全天候无创观察到最近通过算法开发的计算机辅助胚胎选择。尽管全球都在采用延时技术,但它对临床结果的真正影响仍然存在争议。本综述旨在探讨延时技术提供的不同功能,讨论孵化、算法、人工智能和非必要治疗干预的监管,同时评估是否比传统技术有任何益处的证据。
{"title":"Time-Lapse Systems: A Comprehensive Analysis on Effectiveness.","authors":"Patricia Fadon,&nbsp;Eleanor Gallegos,&nbsp;Salonika Jalota,&nbsp;Lourdes Muriel,&nbsp;Cesar Diaz-Garcia","doi":"10.1055/s-0041-1742149","DOIUrl":"https://doi.org/10.1055/s-0041-1742149","url":null,"abstract":"<p><p>Time-lapse systems have quickly become a common feature of in vitro fertilization laboratories all over the world. Since being introduced over a decade ago, the alleged benefits of time-lapse technology have continued to grow, from undisturbed culture conditions and round the clock, noninvasive observations to more recent computer-assisted selection of embryos through the development of algorithms. Despite the global uptake of time-lapse technology, its real impact on clinical outcomes is still controversial. This review aims to explore the different features offered by time-lapse technology, discussing incubation, algorithms, artificial intelligence and the regulation of nonessential treatment interventions, while assessing evidence on whether any benefit is offered over conventional technology.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"e12-e18"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39804761","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Ovarian Hyperstimulation: Diagnosis, Prevention, and Management. 卵巢过度刺激:诊断、预防和管理。
IF 2.7 3区 医学 Q3 OBSTETRICS & GYNECOLOGY Pub Date : 2021-11-01 Epub Date: 2021-10-13 DOI: 10.1055/s-0041-1736492
Paolo Emanuele Levi-Setti, Noemi Di Segni, Clara Gargasole, Camilla Ronchetti, Federico Cirillo

Ovarian hyperstimulation syndrome (OHSS) is a severe complication of controlled ovarian stimulation (COS). Pathogenesis of the disease is based on massive transudation of protein-rich fluid from the vascular compartment into the peritoneal, pleural and pericardial spaces, with a variable picture of clinical manifestations depending on its severity. Nowadays OHSS can easily be avoided by several prevention methods, ranging from identification of high-risk patients, choice of a correct protocol stimulation, trigger with gonadotropin-releasing hormone (GnRH) agonists or, finally, the freeze-all strategy. When OHSS occurs, it can usually be managed as outpatient care. Only if severe/critical cases are diagnosed hospitalization is necessary for appropriate rehydration, monitoring of fluid balance and eventual drainage of ascitic fluid. One of the most dangerous complications of OHSS is venous thromboembolism (VTE). Thromboprophylaxis has shown to be cost effective and widely used, while there are controversies regarding the usage of low dose aspirin (LDA) as a preventive measure.

卵巢过度刺激综合征(OHSS)是控制性卵巢刺激(COS)的严重并发症。该病的发病机制是基于富含蛋白质的液体从血管室大量转流到腹膜、胸膜和心包间隙,其临床表现因其严重程度而异。现在,通过几种预防方法可以很容易地避免OHSS,包括识别高危患者,选择正确的方案刺激,使用促性腺激素释放激素(GnRH)激动剂触发,或者最后,冻结所有策略。当OHSS发生时,通常可以作为门诊护理进行管理。只有在诊断出严重/危重病例时,才需要住院进行适当的补液,监测液体平衡并最终排出腹水。OHSS最危险的并发症之一是静脉血栓栓塞(VTE)。血栓预防已被证明具有成本效益和广泛应用,而关于使用低剂量阿司匹林(LDA)作为预防措施存在争议。
{"title":"Ovarian Hyperstimulation: Diagnosis, Prevention, and Management.","authors":"Paolo Emanuele Levi-Setti,&nbsp;Noemi Di Segni,&nbsp;Clara Gargasole,&nbsp;Camilla Ronchetti,&nbsp;Federico Cirillo","doi":"10.1055/s-0041-1736492","DOIUrl":"https://doi.org/10.1055/s-0041-1736492","url":null,"abstract":"<p><p>Ovarian hyperstimulation syndrome (OHSS) is a severe complication of controlled ovarian stimulation (COS). Pathogenesis of the disease is based on massive transudation of protein-rich fluid from the vascular compartment into the peritoneal, pleural and pericardial spaces, with a variable picture of clinical manifestations depending on its severity. Nowadays OHSS can easily be avoided by several prevention methods, ranging from identification of high-risk patients, choice of a correct protocol stimulation, trigger with gonadotropin-releasing hormone (GnRH) agonists or, finally, the freeze-all strategy. When OHSS occurs, it can usually be managed as outpatient care. Only if severe/critical cases are diagnosed hospitalization is necessary for appropriate rehydration, monitoring of fluid balance and eventual drainage of ascitic fluid. One of the most dangerous complications of OHSS is venous thromboembolism (VTE). Thromboprophylaxis has shown to be cost effective and widely used, while there are controversies regarding the usage of low dose aspirin (LDA) as a preventive measure.</p>","PeriodicalId":21661,"journal":{"name":"Seminars in reproductive medicine","volume":"39 5-06","pages":"170-179"},"PeriodicalIF":2.7,"publicationDate":"2021-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"39514176","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 3
期刊
Seminars in reproductive medicine
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1